DaVita Inc.
Financial and operating highlights include:
-- Continental U.S. dialysis revenue per treatment (excluding lab,
management fees and other revenue) in the first quarter was $274.22 as
compared to $266.51 in the fourth quarter, or a 2.9% sequential
increase.
-- Continental U.S. DSO at quarter end was 71 days. This represents a
2-day improvement from the end of the fourth quarter of 2000.
-- The continental U.S. EBITDA margin for the first quarter was 22.5% as
compared to 21.5% for the fourth quarter of 2000.
-- Operating cash flow for the three months ended March 31, 2001 was
$58 million, in line with our 2001 forecast of $200-$260 million.
-- Total continental U.S. treatments for the first quarter were
1,366,468. Both non-acquired and same center treatment growth were
4.0%.
-- At March 31, 2001 we operated 486 outpatient centers in the continental
U.S. serving 41,000 patients. During the first quarter we closed
1 under-performing center and acquired 13 previously managed centers.
Included in our continental patient and center count are 3,300 patients
in 34 centers under management.
Other developments:
-- In April the Company completed the sale of $225 million of its
9 1/4% Senior Subordinated Notes. The net proceeds of this offering
were used to pay down amounts outstanding under the Company's senior
credit facilities. Additionally on May 4, the Company completed a
refinancing of its existing senior credit facilities. The new credit
facilities include $250 million of term loan borrowings and a revolving
credit facility with $150 million of unused availability.
DaVita will hold a conference call to discuss its first quarter 2001 results and revised financial outlook on Monday, May 7, 2001 at noon Pacific time, 3 PM Eastern time. The dial-in number is 800-399-4406. A replay of the conference call will be available on DaVita's official web page, http://www.davita.com/, for the following 90 days.
This release contains forward-looking statements. Factors which could impact future results include the uncertainties associated with governmental regulation, general economic and other market conditions, and the risk factors set forth in the Company's SEC filings, including its Form 10-K for the year ended December 31, 2000. These risks include those relating to (1) possible reductions in private and government reimbursement rates, (2) the concentration of profits generated from private indemnity patients, (3) the ongoing payment suspension and review of the Company's Florida laboratory subsidiary by its Medicare carrier and the Department of Justice, (4) the ongoing review by the Civil Division of the US Attorney's Office for the Eastern District of Pennsylvania and (5) the Company's ability to maintain contracts with physician medical directors. The forward-looking statements should be considered in light of these risks and uncertainties.
DAVITA INC.
CONSOLIDATED BALANCE SHEETS
(dollars in thousands)
March 31, December 31,
2001 2000
ASSETS
Cash and cash equivalents $17,443 $31,207
Accounts receivable, less allowance of
$60,790 and $61,619 299,424 290,412
Inventories 45,566 20,641
Other current assets 14,259 10,293
Income taxes receivable 2,830
Deferred income taxes 42,265 42,492
Total current assets 418,957 397,875
Property and equipment, net 242,797 236,659
Intangible assets, net 947,946 921,623
Investments in third-party dialysis
businesses 12,203 34,194
Other long-term assets 2,205 1,979
Deferred taxes 1,629 4,302
$1,625,737 $1,596,632
LIABILITIES AND SHAREHOLDERS' EQUITY
Accounts payable $77,345 $74,882
Other liabilities 106,781 102,563
Accrued compensation and benefits 72,484 70,406
Current portion of long-term debt 7,580 1,676
Income taxes payable 15,503
Total current liabilities 279,693 249,527
Long-term debt 932,025 974,006
Other long-term liabilities 4,755 4,855
Minority interests 21,045 18,876
Shareholders' equity
Preferred stock ($0.001 par value; 5,000,000
shares authorized; none issued or
Outstanding)
Common stock ($0.001 par value, 195,000,000
shares authorized; 82,943,817 and 82,135,634
shares issued and outstanding) 83 82
Additional paid-in capital 438,509 430,676
Notes receivable from shareholders (83)
Accumulated deficit (50,373) (81,307)
Total shareholders' equity 388,219 349,368
$1,625,737 $1,596,632
DAVITA INC.
CONSOLIDATED STATEMENTS OF INCOME
(dollars in thousands)
Three months ended
March 31,
2001
Net operating revenues $386,217
Operating expenses:
Dialysis centers and labs 260,974
General and administrative 31,813
Depreciation and amortization 26,148
Provision for uncollectible accounts (8,185)
Total operating expenses 310,750
Operating income 75,467
Other income 1,348
Debt expense 19,724
Minority interests in income of consolidated
subsidiaries (2,457)
Income before income taxes 54,634
Income tax expense 23,700
Net income 30,934
Earnings per share-basic $0.37
Earnings per share-assuming dilution $0.35
Diluted weighted average and incremental shares 102,200,931
Supplemental information:
Continental treatments 1,366,468
Continental EBITDA, excluding recoveries $86 million
Operating cash flow $58 million
Diluted earnings per share, excluding accounts
receivable recoveries $0.24
SOURCE: DaVita Inc.
Contact: LeAnne Zumwalt, Investor Relations of DaVita Inc.,
310-750-2072
Website: http://www.davita.com/